The US Food and Drug Administration (FDA) has granted accelerated approval to teclistamab (Tecvayli, Janssen Biotech, Inc.) for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
